Martin, Peter

Publications

Sort by

Co-Author Network

selected publications

Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood advances. 2023 Academic Article GET IT
Locus specific human endogenous retroviruses reveal new lymphoma subtypes. bioRxiv : the preprint server for biology. 2023 Article GET IT
Times cited: 3855
Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. Transplantation and cellular therapy. 2023 Academic Article GET IT
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 Academic Article GET IT
Times cited: 5
Long COVID in Cancer: A Matched Cohort Study of 1-year Mortality and Long COVID Prevalence Among Patients With Cancer Who Survived an Initial Severe SARS-CoV-2 Infection. American journal of clinical oncology. 2023 Academic Article GET IT
Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood. 2023 Academic Article GET IT
Times cited: 1
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. American journal of hematology. 2023 Academic Article GET IT
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leukemia & lymphoma. 2023 Academic Article GET IT
Evaluating the impact of eligibility criteria in first-line clinical trials for follicular lymphoma: a MER/LEO cohort analysis. Blood advances. 2022 Academic Article GET IT
Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 4
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 11
Unmet mental health needs in patients with advanced B-cell lymphomas. Palliative & supportive care. 2022 Academic Article GET IT
Times cited: 2
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood advances. 2022 Academic Article GET IT
An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood advances. 2022 Academic Article GET IT
Times cited: 7
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. The Lancet. Haematology. 2022 Academic Article GET IT
Times cited: 12
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 2022 Academic Article GET IT
Times cited: 13
Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma Patients. Clinical lymphoma, myeloma & leukemia. 2022 Academic Article GET IT
Times cited: 1
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood advances. 2022 Academic Article GET IT
Times cited: 4
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood advances. 2021 Academic Article GET IT
Times cited: 13
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma. Haematologica. 2021 Academic Article GET IT
Times cited: 6
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. Cancer research. 2021 Academic Article GET IT
Times cited: 8
Serologic response to mRNA COVID-19 vaccination in lymphoma patients. American journal of hematology. 2021 Letter GET IT
Times cited: 22
Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study. Clinical lymphoma, myeloma & leukemia. 2021 Academic Article GET IT
Times cited: 3
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. American journal of hematology. 2021 Academic Article GET IT
Times cited: 9
An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2021 Academic Article GET IT
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. Blood advances. 2021 Academic Article GET IT
Times cited: 12
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. Haematologica. 2021 Academic Article GET IT
Times cited: 12
Acalabrutinib in treatment-naive chronic lymphocytic leukemia. Blood. 2021 Academic Article GET IT
Times cited: 30
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. European journal of haematology. 2021 Academic Article GET IT
Times cited: 3
Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma?. Clinical advances in hematology & oncology : H&O. 2021 Review GET IT
Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosis. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 2
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. Journal of clinical medicine. 2021 Review GET IT
Times cited: 5
Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. The American journal of surgical pathology. 2021 Academic Article GET IT
Times cited: 8
Evaluation of the prognostic utility of bone marrow biopsy in diffuse large B-Cell lymphoma in the SEER-Medicare dataset. Leukemia & lymphoma. 2021 Academic Article GET IT
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
Burkitt Lymphoma International Prognostic Index. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Academic Article GET IT
Times cited: 16
Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. Blood. 2021 Academic Article GET IT
Times cited: 40
Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas. Leukemia & lymphoma. 2020 Academic Article GET IT
Times cited: 9
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis. Blood advances. 2020 Academic Article GET IT
Times cited: 47
COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 93
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals. Gynecologic oncology. 2020 Academic Article GET IT
Times cited: 26
SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer cell. 2020 Academic Article GET IT
Times cited: 147
Watch and Wait in Mantle Cell Lymphoma. Hematology/oncology clinics of North America. 2020 Review GET IT
Times cited: 4
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA: a cancer journal for clinicians. 2020 Academic Article GET IT
Times cited: 12
Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. Blood advances. 2020 Academic Article GET IT
Times cited: 13
An update on options of therapy for aggressive mantle cell lymphoma. Leukemia & lymphoma. 2020 Review GET IT
Times cited: 1
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. Blood. 2020 Academic Article GET IT
Times cited: 106
Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma. Clinical lymphoma, myeloma & leukemia. 2020 Review GET IT
Times cited: 8
Infiltrative Lymphoma-Associated Bradycardia and Cardiac Conduction Abnormalities. JACC. CardioOncology. 2020 Review GET IT
Times cited: 4
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma. British journal of haematology. 2020 Academic Article GET IT
Times cited: 16
Targeting CDK4/6 in mantle cell lymphoma. Annals of lymphoma. 2020 Academic Article GET IT
Lymphoma Study Titles on ClinicalTrials.gov Lack Details Necessary for Study Identification. Clinical lymphoma, myeloma & leukemia. 2019 Academic Article GET IT
Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma. Journal of palliative medicine. 2019 Academic Article GET IT
Times cited: 4
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 18
To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019 Academic Article GET IT
The optimal chemotherapy regimen for primary mediastinal B-cell lymphoma: we may never know. Leukemia & lymphoma. 2019 Comment GET IT
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop. Leukemia & lymphoma. 2019 Conference Paper GET IT
Times cited: 7
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 50
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. British journal of haematology. 2018 Academic Article GET IT
Times cited: 24
The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer medicine. 2018 Academic Article GET IT
Times cited: 26
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 69
Improving implementation of psychological interventions to older adult patients with cancer: Convening older adults, caregivers, providers, researchers. Journal of geriatric oncology. 2018 Academic Article GET IT
Times cited: 16
Bridging the Gap Between Aging Research and Practice: A New Strategy for Enhancing the Consensus Workshop Model. Journal of applied gerontology : the official journal of the Southern Gerontological Society. 2018 Academic Article GET IT
Times cited: 6
A tale of two mantle cell lymphomas. Blood. 2018 Comment GET IT
Times cited: 2
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 61
Management of relapsed/refractory follicular lymphoma. Clinical advances in hematology & oncology : H&O. 2018 Academic Article GET IT
Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 35
A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. British journal of haematology. 2017 Letter GET IT
Times cited: 3
Optimizing therapy for mantle cell lymphoma. Hematology. American Society of Hematology. Education Program. 2017 Review GET IT
Times cited: 3
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). Journal of hematology & oncology. 2017 Academic Article GET IT
Times cited: 26
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 64
CARs on a highway with roadblocks. Oncoimmunology. 2017 Editorial Article GET IT
Times cited: 6
The potential for chemotherapy-free strategies in mantle cell lymphoma. Blood. 2017 Review GET IT
Times cited: 9
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials. British journal of haematology. 2017 Academic Article GET IT
Times cited: 10
Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Review GET IT
Times cited: 50
Mantle cell lymphoma - Current standards of care and future directions. Cancer treatment reviews. 2017 Review GET IT
Times cited: 16
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 6
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017 Academic Article GET IT
Times cited: 101
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma. British journal of haematology. 2017 Academic Article GET IT
Times cited: 25
Long-term safety experience with bendamustine for injection in a real-world setting. Expert opinion on drug safety. 2017 Academic Article GET IT
Times cited: 3
The use of CAR T cells in diffuse large B-cell lymphoma and mantle cell lymphoma. Clinical advances in hematology & oncology : H&O. 2017 Academic Article GET IT
Times cited: 2
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. Blood. 2017 Letter GET IT
Times cited: 67
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017 Academic Article GET IT
Times cited: 211
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute. 2016 Review GET IT
Times cited: 11
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica. 2016 Letter GET IT
Times cited: 63
Bendamustine-rituximab in mantle cell lymphoma. The Lancet. Haematology. 2016 Academic Article GET IT
Times cited: 6
Frontline autologous stem cell transplant for high-risk follicular lymphoma: forever elusive?. Leukemia & lymphoma. 2016 Comment GET IT
Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood cancer journal. 2016 Academic Article GET IT
Times cited: 43
Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update. Immunotherapy. 2016 Review GET IT
Times cited: 7
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016 Academic Article GET IT
Times cited: 44
Evaluating Quality Metrics for the Care of Patients With Blood Cancer Who Are Near Death. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
Times cited: 2
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical epigenetics. 2016 Academic Article GET IT
Times cited: 35
Mantle cell lymphoma treatment: plus ça change…. Lancet (London, England). 2016 Comment GET IT
Times cited: 3
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. American journal of hematology. 2016 Academic Article GET IT
Times cited: 44
Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy. Current hematologic malignancy reports. 2016 Review GET IT
Times cited: 9
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Review GET IT
Times cited: 5
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. 2016 Academic Article GET IT
Times cited: 25
Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 191
Role of Surveillance Imaging in Patients With Peripheral T-Cell Lymphoma. Clinical lymphoma, myeloma & leukemia. 2015 Academic Article GET IT
Times cited: 9
Ibrutinib--a new standard treatment for relapsed mantle cell lymphoma?. Lancet (London, England). 2015 Comment GET IT
Times cited: 7
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 182
High-dose cytarabine in mantle cell lymphoma. Clinical advances in hematology & oncology : H&O. 2015 Review GET IT
Times cited: 1
Is the open mouth mightier than the needle?. Blood. 2015 Comment GET IT
Correlation of Changes in Gait Parameters, With Phenotype, Outcome Measures, and Electrodiagnostic Abnormalities in a Patient With Anti-MAG Neuropathy After Exacerbation and Improvement. 2015 GET IT
Times cited: 7
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015 Academic Article GET IT
Times cited: 112
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Academic Article GET IT
Times cited: 309
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 16
Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 13
Lymphoblastic transformation of follicular lymphoma: a clinicopathologic and molecular analysis of 7 patients. Human pathology. 2014 Academic Article GET IT
Times cited: 54
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood cancer journal. 2014 Academic Article GET IT
Times cited: 42
Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology. Current hematologic malignancy reports. 2014 Academic Article GET IT
Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome biology. 2014 Academic Article GET IT
Times cited: 74
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 212
When indolent follicular lymphoma is not indolent. Leukemia & lymphoma. 2014 Comment GET IT
Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. British journal of haematology. 2014 Academic Article GET IT
Times cited: 76
Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab. Leukemia & lymphoma. 2014 Academic Article GET IT
Times cited: 9
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. British journal of haematology. 2014 Academic Article GET IT
Times cited: 70
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. The New England journal of medicine. 2014 Academic Article GET IT
Times cited: 859
Watching and waiting in mantle cell lymphoma. Clinical advances in hematology & oncology : H&O. 2013 Article GET IT
Times cited: 1
Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: clinical and correlative results. Clinical lymphoma, myeloma & leukemia. 2013 Academic Article GET IT
Times cited: 12
Indolent mantle cell lymphoma. Leukemia & lymphoma. 2013 Review GET IT
Times cited: 26
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. Cancer. 2013 Academic Article GET IT
Times cited: 18
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer discovery. 2013 Academic Article GET IT
Times cited: 149
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 1265
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell cycle (Georgetown, Tex.). 2013 Academic Article GET IT
Times cited: 2040
Limited-stage mantle cell lymphoma: not so different from advanced-stage. Leukemia & lymphoma. 2012 Comment GET IT
Times cited: 1
Autologous stem cell transplant in human immunodeficiency virus-positive patients with lymphoid malignancies: focus on infectious complications. Leukemia & lymphoma. 2012 Letter GET IT
Times cited: 3
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 19
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leukemia & lymphoma. 2012 Academic Article GET IT
Times cited: 23
Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches. Cancer control : journal of the Moffitt Cancer Center. 2012 Review GET IT
Times cited: 38
Management of mantle cell lymphoma in the elderly. Best practice & research. Clinical haematology. 2012 Review GET IT
Times cited: 6
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology (Amsterdam, Netherlands). 2012 Academic Article GET IT
Times cited: 18
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012 Academic Article GET IT
Times cited: 256
Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. American journal of hematology. 2012 Letter GET IT
Times cited: 33
Splenic lymphomas: is there still a role for splenectomy?. Oncology (Williston Park, N.Y.). 2012 Comment GET IT
Times cited: 2
CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1: biomarkers in search of validation in lymphomas. Leukemia & lymphoma. 2012 Comment GET IT
Times cited: 1
Low-grade follicular lymphoma of the small intestine: a challenge for management. 2011 GET IT
Times cited: 3
Is there a role for "watch and wait" in patients with mantle cell lymphoma?. Seminars in hematology. 2011 Review GET IT
Times cited: 22
Advancing through maintenance in mantle cell lymphoma. Leukemia & lymphoma. 2011 Comment GET IT
Toxicity burden score: a novel approach to summarize multiple toxic effects. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 39
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 278
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 46
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010 Academic Article GET IT
Times cited: 52
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical lymphoma, myeloma & leukemia. 2010 Academic Article GET IT
Times cited: 45
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 45
Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 140
When 18-fluorodeoxyglucose-positron emission tomography is indeterminate, the International Prognostic Index is the answer. Leukemia & lymphoma. 2010 Comment GET IT
Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 43
Novel agents for follicular lymphoma. Hematology. American Society of Hematology. Education Program. 2010 Academic Article GET IT
Times cited: 8
Is there a role for bone scan in Hodgkin lymphoma in the age of 18F-fluorodeoxyglucose positron emission tomography?. Leukemia & lymphoma. 2009 Comment GET IT
Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. 2009 GET IT
Times cited: 4
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 286
Milatuzumab: a promising new agent for the treatment of lymphoid malignancies. Expert opinion on investigational drugs. 2009 Review GET IT
Times cited: 19
Progress in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Editorial Article GET IT
Times cited: 19
Expression of the follicular lymphoma variant translocation 1 gene in diffuse large B-cell lymphoma correlates with subtype and clinical outcome. American journal of clinical pathology. 2008 Academic Article GET IT
Times cited: 5
New biologic agents and immunologic strategies. Hematology/oncology clinics of North America. 2008 Review GET IT
Times cited: 6
Targeted treatment and new agents in diffuse large B-cell lymphoma. Seminars in hematology. 2008 Review GET IT
Times cited: 22
New monoclonal antibodies for non-Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Review GET IT
Times cited: 5
Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer. 2008 Academic Article GET IT
Times cited: 59
FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 15
Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Seminars in hematology. 2008 Review GET IT
Times cited: 16
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 66
Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leukemia & lymphoma. 2008 Academic Article GET IT
Times cited: 35
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Review GET IT
Times cited: 11
Targeted therapies for non-Hodgkin lymphoma: rationally designed combinations. Clinical lymphoma & myeloma. 2007 Review GET IT
Times cited: 4
IL-4 as therapy for non-Hodgkin's lymphoma: possibilities but major challenges. Leukemia & lymphoma. 2007 Comment GET IT
Times cited: 1
Novel therapeutic targets in mantle cell lymphoma. Expert opinion on therapeutic targets. 2007 Review GET IT
Times cited: 4

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma awarded by National Cancer Institute Co-Investigator 2021 - 2026
Communicating the gist of prognosis: An intervention to improve prognostic understanding in advanced lymphoma awarded by National Institute of Diabetes & Digestive & Kidney Diseases Co-Investigator 2022 - 2024
Mechanism-Based Targeting of Mantle Cell Lymphoma awarded by National Cancer Institute Co-Investigator 2018 - 2024

Longitudinal functional genomics in mantle cell lymphoma therapy and drug resistance awarded by Leukemia & Lymphoma Society, Inc. Key Personnel 2018 - 2023

The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study awarded by Genentech, Inc. Principal Investigator Subaward 2021 - 2026
The Lymphoma Epidemiology of Outcomes (LEO) awarded by Genentech, Inc. Principal Investigator Subaward 2023 - 2024
Characteristics and Outcomes of Patients with Follicular Lymphoma with at Least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers within the LEO Cohort awarded by Genentech, Inc. Principal Investigator Subaward 2022 - 2024

more ...

less ...

Background

education and training

M.S., Cornell University 2008
M.D., University of Alberta Faculty of Medicine (Canada) 2001
B.S., University of Alberta (Canada) 1995

Contact

full name

Peter Martin

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Peter Martin Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

webpage